People that use Acomplia Rimonabant must be more carreful and pay attention to a problem that producer Sanofi-Aventis is now facing : If people don’t want to gain back the weight they lost on Acomplia, people are obligated to take this medication every day for the rest of their life.
In the Phase III clinical trials for Acomplia Rimonabant, people who were on rimonabant for a year lost up to 10 percent of their body weight. But while those who continued on Acomplia for a second year maintained their weight loss, those switched to a placebo tended to quickly regain the weight.
That could only suggest that if you want to keep weight lost while taking Acomplia Rimonabant from returning, people must take rimonabant indefinitely — a point the FDA advisory panel picked up on in majority and in conclusion that not enough long-term safety data had been submitted by producer Sanofi.
The FDA advisory panel declared in the minutes of the reunion that :”There was general agreement among the committee that there needs to be more long-term data; the concern being that of having limited 2-year study data being used to assess a medication that is going to be used for a longterm,”
Cluzel said “With any kind of chronic disease, when you stop the treatment — in fact, whether you are taking an antihypertensive medication, when you abandon the treatment you gain a really high blood pressure,and we think that it’s the case of Acomplia Rimonabant”
Cluzel,also said on the advisory panel statement “My opinion is that the review committee took recognizance at this moment that obesity is a chronic disease, and I think that is the spirit of the comment’’.
A frequently used teory which consernes obesity treatment is that 95 percent of patiens who lose weight gain it all back.
A statistic study about this is based on a small study from 1960,but of course is no longer valid. Lots off new things apperes and other have changed conserning obesity treatment since then. Thousands of people have succeeded in losing weight and keeping it off — an encouraging fact for many that are discouraged by outdated information.
In our days are several different types of obesity treatment options to manage weight that are really effective including: dietary therapy, physical activity, behavior therapy, drug therapy, combined therapy and surgery. Weight loss of about 10 percent of body weight has proved to benefit the human health by reducing many obesity-related risk factors.
Recommendations for treatment are now focusing on 10 percent weight loss to help patients with long-term maintenance of weight loss. Health professionals including physicians, nutritionists, exercise physiologists, psychologists and bariatric surgeons help persons with overweight and obesity to determine the most appropriate treatment.
Drug Therapy as a very important obesity traetment in our days(drugs like Rimonabant Acomplia )
- Drug therapy can be used as a treatment option for persons with: 1) a Body Mass Index (BMI) > 30 with no obesity-related conditions or 2) a BMI of > 27 with two or more obesity-related conditions.
- Drug treatment can be used if the patient is willing to have also an appropriate lifestylein order af a better result.
- Drug therapy may be used for weight loss and weight maintenance.
- People should be regularly assessed to determine the effect and continuing safety of a drug.
- Three weight loss drugs, approved by the US Food and Drug Administration (FDA) for treating obesity, are Orlistat (Xenical), Phentermine, and Sibutramine (Meridia) the the newest and better is Rimonabant Acomplia .
1. Orlistat works by blocking about 30 percent of dietary fat from being absorbed, and is the most recently approved weight loss drug.
2. Phentermine, an appetite suppressant, has been available for many years. It is half of the “fen-phen” combination that remains available for use. The use of phentermine alone has not been associated with the adverse health effects of the fenfluramine-phentermine combination.
3. Sibutramine is approved for long-term use, and works to control eating by sending a signal of fullness (satiety) to the brain.
4. The obesity treatment with Rimonabant Acomplia is very efficient because it works by blocking the receptors located in the brain that are responsble with the appetite.